Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alpine Immune Sciences Inc | 4.5B | --- | --- |
Krystal Biotech Inc | 4.7B | 87.4x | --- |
Immunovant Inc | 4.5B | -16.9x | --- |
Nuvalent Inc | 4.6B | -29.4x | --- |
Madrigal Pharmaceuticals Inc | 4.7B | -10.1x | --- |
Crinetics Pharmaceuticals Inc | 4.1B | -13.4x | --- |
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
---|---|
Revenue (TTM) | $56.5M |
Shares Outstanding | 68.6M |
Alpine Immune Sciences Inc does not pay a dividend. | |
Beta | 0.84 |
EPS | $-0.68 |
Book Value | $5.43 |
P/E Ratio | --- |
Price/Sales (TTM) | 78.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -90.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.